Nephrocare Health Services Limited
Nephrocare Health Services Limited operates in Healthcare Service Provider, part of the Healthcare sector. It booked ₹303 cr of revenue in its latest quarter (Q2 FY27) and kept 11.1% of sales as profit. It is the 5th largest of 9 Healthcare Service Provider companies we track, by market value.
Healthier than 63% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 118–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 45
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in NEPHROPLUS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 5%, taken from a generic assumption, not this company's history. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹303 cr |
| Other Income | ₹8 cr |
| Total Income | ₹311 cr |
| Cost of Materials | ₹66 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Employee Benefit Expense | ₹53 cr |
| Finance Costs | ₹3 cr |
| Depreciation & Amortisation | ₹28 cr |
| Other Expenses | ₹117 cr |
| Total Expenses | ₹267 cr |
| Profit before Tax | ₹44 cr |
| Tax Expense | ₹7 cr |
| Share of JV / Associates | ₹-4 cr |
| Net Profit | ₹34 cr |
| Net margin on total income | 10.8% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 266 cr | 282 cr | 303 cr |
| Total income | 277 cr | 289 cr | 311 cr |
| Expenses | 241 cr | 245 cr | 267 cr |
| Profit before tax | 36 cr | 45 cr | 44 cr |
| Tax | 3 cr | 9 cr | 7 cr |
| Net profit (owners' share) | 30 cr | 32 cr | 34 cr |
| Net margin (owners' share, on revenue) | 11.4% | 11.3% | 11.1% |
| EPS (₹) | 3.03 | 3.19 | 3.34 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd. | ₹1,926 | ₹32,275 cr | 47.4 | 27.0% | 21.2% | — |
| Vijaya Diagnostic Centre Limited | ₹1,447 | ₹14,890 cr | 70.1 | 22.2% | 23.0% | — |
| Metropolis Healthcare Limited | ₹569 | ₹11,791 cr | 52.1 | 15.0% | 12.6% | — |
| Thyrocare Technologies Limited | ₹483 | ₹7,686 cr | 125.8 | 11.5% | 5.9% | — |
| Nephrocare Health Services Limitedthis company | ₹625 | ₹6,281 cr | 46.8 | 11.3% | 11.1% | — |
| Suraksha Diagnostic Limited | ₹324 | ₹1,686 cr | 32.4 | 21.3% | 14.8% | — |
| Krsnaa Diagnostics Limited | ₹486 | ₹1,576 cr | 15.9 | 9.5% | 9.1% | — |
| Health X Platform Limited | ₹281 | ₹895 cr | 87.9 | 1.6% | 0.6% | — |
| Gaudium IVF and Women Health Limited | ₹108 | ₹786 cr | 107.9 | 4.7% | 9.2% | — |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 8 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.
When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.
As of Sep 2026, the company says it has spent 68% of what it set aside, leaving ₹114 cr still to be spent. Crisil Ratings Limited watches the spending on the exchange’s behalf.
Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing